Cidara Cuts Workforce to Prioritize CD388 for Influenza Prevention

Thursday, 12 September 2024, 21:14

Cidara is cutting 30% of its workforce to intensively focus on CD388, a promising drug-Fc conjugate candidate for influenza A and B prevention. This strategic move aims to optimize resources towards developing an innovative solution in influenza treatments. The decision underscores the company's commitment to advancing healthcare technology and pharmaceuticals.
Seekingalpha
Cidara Cuts Workforce to Prioritize CD388 for Influenza Prevention

Cidara's Workforce Reduction

Cidara (CDTX) announced a workforce reduction of approximately 30% in a strategic pivot to emphasize its drug-Fc conjugate candidate, CD388. This decision aims to channel resources effectively towards developing an innovative treatment option for influenza A and B.

Implications of Focusing on CD388

The prioritization of CD388 reflects Cidara's commitment to advancing healthcare technology and addressing significant public health challenges posed by influenza. The restructuring showcases their dedication to delivering impactful pharmaceutical solutions that could transform patient care in the future.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe